Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.41 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23881819 | 0.91 | L3MBTL1 (0.47) | PPARDL3MBTL1MAPTHPGDATM | |
| SCHEMBL29474947 | 0.91 | L3MBTL1 (0.47) | PPARDL3MBTL1MAPTHPGDATM | |
| SCHEMBL2806322 | 0.86 | L3MBTL1 (0.50) | PPARDL3MBTL1MAPTHPGDATM | |
| SCHEMBL7759613 | 0.84 | CYP1A2 (0.53) | PPARDL3MBTL1MAPTHPGDATM | |
| SCHEMBL10335287 | 0.83 | ALDH1A1 (0.48) | L3MBTL1MAPTHPGDNPSR1ALDH1A1 | |
| SCHEMBL27449242 | 0.83 | TAAR1 (0.62) | PPARDL3MBTL1MAPTHPGDATM | |
| SCHEMBL24808599 | 0.83 | MAPT (0.50) | PPARDL3MBTL1MAPTNPSR1LTB4R | |
| SCHEMBL27761600 | 0.82 | TAAR1 (0.43) | ALDH1A1 | |
| SCHEMBL5661565 | 0.82 | MAPT (0.49) | PPARDL3MBTL1MAPTHPGDATM | |
| SCHEMBL13490745 | 0.80 | L3MBTL1 (0.70) | PPARDL3MBTL1MAPTHPGDATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178559-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-05-15 | — | — | US | disclosed |
| US-8178559-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-05-15 | — | — | US | disclosed |
| US-8084450-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-8084450-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20110263560-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-10-27 | — | — | US | disclosed |
| US-20110263560-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-10-27 | — | — | US | disclosed |
| EP-2177518-A1 | Organic compounds | Novartis AG (CH) | 2010-04-21 | — | — | EP | disclosed |
| US-20090312304-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
| US-20090312304-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
| EP-1833816-B1 | SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2009-11-11 | — | — | EP | disclosed |
| WO-2006069788-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263560-A1 | Organic Compounds | REN, ACE, OTC | PPARD 160/4885L3MBTL1 4255/4885MAPT 1212/4885 |
| US-20090312304-A1 | ORGANIC COMPOUNDS | REN, ACE, PIGO | PPARD 307/4885L3MBTL1 4645/4885MAPT 1109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.